Related Experiment Video
Updated: Oct 15, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.3K
Treatment of systemic sclerosis
Benjamin Thoreau1, Benjamin Chaigne1, Arthur Renaud2
1Institut Cochin, INSERM U1016, CNRS UMR 8104, Université de Paris; Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d'Ile de France, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Presse Medicale (Paris, France : 1983)
|October 31, 2021
Summary
Systemic sclerosis (SSc) management involves regular organ damage assessment and targeted therapies. Advances in personalized medicine improve survival and prognosis for patients with this rare fibrotic disease.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Systemic sclerosis (SSc) is a rare, severe connective tissue disease.
- Characterized by fibrosis, vascular issues, and potential organ damage (lung, heart).
- Complications significantly increase mortality and worsen prognosis.
Purpose of the Study:
- To review clinical trial outcomes for SSc management.
- To highlight advances in treating SSc complications.
- To emphasize the role of personalized medicine in SSc.
Main Methods:
- Review of randomized clinical trials in Systemic Sclerosis.
- Analysis of therapeutic strategies for SSc organ involvements.
- Assessment of advancements in targeted and personalized medicine.
Main Results:
- Clinical trials demonstrate positive outcomes for specific SSc involvements.
- Targeted therapies and personalized medicine show significant progress.
- Regular assessment and graduated treatment strategies improve patient outcomes.
Conclusions:
- SSc management requires continuous monitoring and tailored therapeutic approaches.
- Personalized medicine, based on patient and disease characteristics, is crucial.
- Ongoing research and clinical trials are vital for improving SSc patient survival and prognosis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
01:26Atherosclerosis III: Management
63
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
01:21Rheumatic Heart Disease III: Medical Management
54
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
54
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
01:31Skeletal Muscle Relaxants: Therapeutic Uses
689
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
689
01:14Myocarditis III: Medical Management
31
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
31